Torsade de Pointes: Mechanisms and Management

Drugs

Volumn 47, Issue 1, 1994, Pages 51-65

  Napolitano, Carlo ^a,b   Priori, Silvia G ^a,b   Schwartz, Peter J ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; ATROPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; ISOPRENALINE; MACROLIDE; MAGNESIUM SULFATE; PHENOTHIAZINE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT;

ELECTROCARDIOGRAM; HEART ELECTROPHYSIOLOGY; LONG QT SYNDROME; PATHOGENESIS; QT INTERVAL; REENTRY ARRHYTHMIA; REVIEW; T WAVE; TORSADE DES POINTES;

CARDIOVASCULAR AGENTS; ELECTROCARDIOGRAPHY; HUMAN; TORSADES DE POINTES;

EID: 0028115856     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199447010-00004     Document Type: Review

References (68)

1. Magnesium suppression of early after depolarizations and ventricular arrhythmias induced by caesium in dogs
2. The long QT syndrome
3. Electrophysiologic testing in patients with the long QT syndrome
4. Recording of monophasic action potentials of the right ventricle in long QT syndromes complicated by severe ventricular arrhythmias
5. Bradycardia-dependent triggered activity: relevance to drug-induced multiform ventricular tachycardia
6. Torsades de Pointes induced by N-acetylprocainamide
7. Ventricular arrhythmias and hypokalemia
8. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals
9. Reduction in QT dispersion by sotalol following myocardial infarction
10. Un chapitre nouveau d’electrocardiographie: les variations progressives de l’amplitude de l’electrocardiogramme
11. La tachycardia ventriculaire a deux foyers opposes variable
12. Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs
13. Long term recording of monophasic action potential from human endocardium
14. In vitro validation of a new catheter technique for recording monophasic action potentials
15. Right ventricular monophasic action potentials in patients with long QT syndrome
16. QT prolongation and recurrent ‘Torsades de Pointes’ during erythromycin lactobionate infusion
17. Drug-induced Torsades de Pointes: role of early afterdepolarizations and dispersion of repolarization
18. Non uniform recovery of excitability in ventricular muscle
19. Precordial QT interval dispersion as a marker of Torsades de Pointes
20. Sudden, unexpected death in avid dieters using the liquid-protein-modifiedfast diet. Observations in 17 patients and the role of prolonged QT interval
21. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis
22. Congenital deaf-mutism, functional heart disease with prolongation of the QT interval and sudden death
23. Management of recurrent ventricular tachyarrhythmias associated with QT prolongation
24. Torsades de Pointes: the long-short initiating sequence and other clinical features
25. Etiology, warning, signs and therapy of Torsades de Pointes. A study of 10 patients
26. Late potentials detected after myocardial infarction: natural history and pathogenetic significance
27. Sotalol induced Torsades de Pointes
28. Characteristics and possible mechanism of ventricular arrhythmia dependent on dispersion of action potential duration
29. ++
30. Idiopathic long QT syndrome exacerbated by beta adrenergic blockade and responsive to left cardiac sympathetic denervation: implications regarding electrophysiologic substrate and adrenergic modulation
31. Open clinical studies at a referral centre. Chronic maintenance tocainide therapy in patients with recurrent sustained ventricular tachycardia refractory to conventional antiarrhythmic agents
32. Torsades de Pointes complicating AV block: report of two cases
33. Block of inactivated sodium channels depolarization induced automaticity in guinea pig papillary muscle by amiodarone
34. Recurrent ventricular tachycardia with QT prolongation after initial valve replacement and its association with intravenous administration of erythromycin
35. Sudden death in phenothiazine therapy
36. Efficacy of permanent pacing in the management of the long QT syndrome
37. The long QT syndrome: a prospective international study
38. The long QT syndrome prospective longitudinal study of 328 families
39. Torsades de Pointes and atrioventricular block
40. Dispersion of ventricular activation in the long QT syndrome
41. Erythromycin-induced long QT syndrome: concordance with Quinidine and underlying cellular electrophysiologic mechanism
42. Polymorphous ventricular tachycardia: clinical characterization, therapy and QT interval
43. Amiodarone blocks calcium current in single guinea pig ventricular myocytes
44. Mechanism underlying early and delayed after depolarizations induced by catecholamine in isolated canine ventricular myocytes
45. Delayed after depolarizations elicited in vivo by left stellate ganglion stimulation
46. Dispersion of repolarization as a marker to predict efficacy of antiadrenergic therapy
47. Dysopiramide-induced QT prolongation and ventricular tachyarrhythmias
48. Clinical features and basic mechanisms of Quinidine-induced arrhythmias
49. Incidence and clinical features of the Quinidine associated long QT syndrome: implications for patient care
50. Aritmie cardiache rare in eta’ pedriatica
51. Electrophysiological mechanism in a canine model of erythromycin-associated long QT syndrome
52. Thioridazine (‘Meilern’) induced ventricular tachycardia controlled with an artificial pacemaker
53. The idiopathic long QT syndrome: progress and questions
54. The idiopathic long QT syndrome: pathogenetic mechanisms and therapy
55. Pathogenesis and therapy of the long QT syndrome
56. Left cardiac sympathetic denervation in the therapy of the congenital long QT syndrome: a worldwide report
57. Polymorphous ventricular tachycardia: clinical features and treatment
58. Mexiletine for treatment of Torsades de Pointes
59. Early after depolarizations induced by isoproterenol in patients with congenital long QT syndrome
60. Quantitative zoology
61. Torsades de pointes: definition, causative factors and therapy. Experience with sixteen patients
62. QT interval prolongation and cardiac arrest during therapy with spiramycin in a new-born infant
63. Procainamide-induced Polymorphous ventricular tachycardia
64. Electrophysiologic substrate of Torsades de Pointes: dispersion of repolarization or early after depolarizations?
65. Magnesium therapy of Torsades de Pointes
66. Disopyramide-induced Torsades de Pointes
67. New familial cardiac syndrome in children
68. After depolarizations and triggered activity